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Abstract: 
  In this studies, three fatty acyl derivatives of CGKRK homing peptides were coupled 
successfully to chitosan oligosaccharides (COS) using sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate sodium salt (sulfo-SMCC). The COS-SMCC was 
prepared by direct coupling between COS and sulfo-SMCC in PBS (pH 7.5) at RT for 48 h. The 
structure of COS-SMCC and the three fatty acyl-CGKRK-SMCC-COS conjugates were 
characterized by FT-IR, 
13
C NMR, and SEM. The ability of three conjugates to condense siRNA 
into nanosized polyplexes and their efficacy in protecting siRNA from serum nucleases 
degradation were investigated. Among the investigated derivatives, S-CGKRK-COS showed 
higher siRNA binding affinity as compared to the P-CGKRK-COS and O-CGKRK-COS 
respectively. At a ratio of 10:1, complete protection for siRNA from early enzymatic degradation 
was achieved. The polymers and the polymer/siRNA polyplexes showed negligible cytotoxicity 
on human breast cancer cell line MDA-MB-231 at all investigated ratios. However, the 
polyplexes prepared with palmitoyl and oleoyl derivatives at polymer concentration 10 µg/mL 
reduced the cell viability by 21.5%  and 35% respectively. The results of this study revealed the 
impact of using fatty acyl-CGKRK-COS as a siRNA carrier and confirmed the importance of 
incorporating a hydrophobic moiety into chitosan to improve its capacity in complexing with 
siRNA and protection from degradation.  
 
Keywords: fatty acyl-CGKRK peptide, chitosan oligosaccharide, MDA-MB-231, siRNA 
delivery, cytotoxicity. 
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1. Introduction 
The term gene therapy covers a wide range of treatments that employ the genetic material to 
modify cell activities. Gene therapy is the next generation strategy for fighting many heredity 
disorders, cancers, infectious, chronic, and neurodegenerative diseases [1]. So far, few 
approaches to gene therapies have been approved. The first gene therapy approved in the China 
was Gendicine in 2003 for the treatment of head and neck squamous cell carcinoma. Using 
Gendicine more than two thousands of patients have been treated alone in the China. Another 
example of the successful launch of gene therapy came in October 2012 in Europe where the 
European Medicines Agency (EMA) gave its permission to a gene therapy company UniQure at 
Amsterdam to approve Glybera, for the treatment of an extremely rare disease that inflames the 
pancreas. Similarly, EMA also approved GlaxoSmithKline together with Fondazione Telethon 
and Ospedale to launch Strimvelis, a pediatric gene therapy product that targets a rare immune 
disorder due to adenosine deaminase deficiency (ADA-SCID) [2].  
Short interfering RNA (siRNA)-mediated gene silencing is an intracellular mechanism 
used for suppressing expression of certain proteins, leading to a phenotypical response. siRNA 
has demonstrated tremendous therapeutic potential for the treatment of many gene associated 
disorders and pathogens [3]. Over the years, several strategies for siRNA efficient delivery have 
been explored including polycationic liposomes, cationic polymers, nanoparticles, aptamers, 
cationic cell-penetrating peptides (CPPs), antibodies, and cationic lipids [4-9]. Despite the high 
gene transfection efficiency of viral carriers, the viral induced immunogenicity and the 
insertional mutagenesis are the major problems that impede their actual use on the clinical levels 
[3]. Due to the cytotoxicity profile, the high-cost effectiveness, and poor siRNA transfection 
efficiency for the non-viral carriers [10], there is a growing interest in developing successful 
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non-viral nucleic acid carriers that can address the safety, biocompatibility, biodegradability, and 
selectivity issues. With a great emphasis on their ability to stabilize their complexes with 
different forms of nucleic acid therapy, escape the phagocytosis, and protect its load from serum 
nucleases degradation [11]. 
Chitosan and its derivatives have inspired the investigators as a promising non-viral 
nucleic acid carrier because of their dense cationic nature, excellent biocompatibility, nearly 
negligible cytotoxicity and immune response. The high flexibility of chitosan backbone permits 
their further modifications to improve its transfection efficacy and selectivity [12, 13]. The 
potential of chitosan and its derivative as nucleic acid carrier is due to the primary amines along 
their backbone, which protonate in the acidic pH to positively charged amine groups that bind to 
the negatively charged DNA or siRNA via the electrostatic interaction, leading to the formation 
of nano-size complexes named polyplexes in the aqueous medium.  Nevertheless, the limited 
siRNA transfection efficiency of chitosan and the lack of tissue selectivity,  have inspired many 
researchers to look for solutions to surmount the aforementioned barriers and mediate siRNA 
transfection using chitosan derivatives.  
Among the suggested approaches that have been investigated to overcome the in vivo 
limitations of siRNA delivery, is PEGylation of the carrier system. It has been found that the 
PEGylation of polycations can ameliorate the polycation toxicity, and prolong the in vivo half-
life for the polyplexes. However, PEG affects the size, charge, stability of the formed polyplexes, 
and may hinder their cellular uptake. Therefore, a balance between PEGylation and de-
PEGylation of the polyplexes is needed to enable the siRNA escape from the phagocytosis by the 
reticuloendothelial system and allow its proper uptake by the cells [12-15]. Furthermore, 
previous studies estimated the importance of incorporating a hydrophobic substituted to the 
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siRNA polymeric carrier. Since the hydrophobic fragment such as oleic acid, and stearic acid, or 
cholesterol significantly enhanced the siRNA cellular uptake, promoted its endosomal release 
into the cytoplasm, protected siRNA against serum nucleases digestion, and effectively improved 
the siRNA transfection efficacy [16-18].   
Furthermore, a unique feature of the CPPs is their efficiency in transporting payloads into 
the target cell through active or passive mechanisms [19]. This feature has been employed to 
improve the chitosan transfection capacity and tissue selectivity through its conjugation to CPPs 
[20]. The attachment of targeting ligand to the drug and gene delivery systems has been found to 
be an effective strategy for achieving selective delivery of the chemotherapeutics to the tumor 
sites, due to the significant differentiation of the tumor tissue from the normal tissues [20, 21]. In 
2011, L. Agemy et al. reported the success of the iron oxide nanoparticles decorated with CGKRK 
peptide in targeting glioblastoma, breast, and prostate cancer cell lines [22, 23]. The targeting by 
CGKRK peptide mediates the cellular internalization in energy and heparin sulfate receptor-
dependent manners, which are overexpressed significantly in the cancer cells [22]. Recently, we 
have developed a library of fatty acyl CGKRK peptides, which were found to be potent in their 
ability to bind to siRNA, protect siRNA from the enzymatic degradation, and selectively target 
breast and prostate cancer cell lines and induced siRNA silencing for kinesin spindle protein 
(KSP) [24]. The results indicated that the stearic/oleic acid-peptide conjugates showed the 
highest efficiency in siRNA uptake and silencing of kinesin spindle protein (KSP) at a peptide: 
siRNA ratio of 80:1. Therefore, we decided to explore the impact of conjugating chitosan 
oligosaccharide to the palmitoyl, stearoyl, and oleoyl CGKRK peptide and evaluate the 
efficiency of the delivery system in the formation of a complex with siRNA and protecting it 
from serum nucleases degradation and dissociation by other competing species such as heparin. 
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2. Materials and methods 
2.1. Materials 
Chitosan oligosaccharides (COS) MW = 4000-5000 Da, with 90% degree of 
deacetylation, palmitic, stearic acid, or oleic acid and 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT), heparin sulfate were purchased from Sigma-Aldrich Chemical Co. 
(Milwaukee, WI, USA). For the synthesis of fatty acyl-CGKRK peptides, all required organic 
solvents were purchased from Wilkem Scientific (Pawtucket, RI, USA). Coupling reagents 
include Rink amide MBHA resin, and Fmoc-amino acid building blocks were purchased from 
Chem-Impex International Inc. (Wood Dale, IL, USA). Other reagents and chemicals were 
purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI, USA).  
Hanks Balanced Salt Solution (HBSS), Dulbecco’s modified Eagle medium (DMEM; 
low glucose with L-glutamine),  RPMI Medium 1640 with L-glutamine, Fetal bovine serum 
(FBS), SYBR Green II, penicillin (10000 U/mL), and streptomycin (10 mg/mL) were provided 
by Life Technologies (Grand Island, NY, USA). Scrambled negative control siRNA (Catalogue 
# AM4635), 5′-carboxyfluorescein (FAM)-labeled negative control siRNA (Catalogue # 
AM4620), and the siRNA targeting kinesin spindle protein (KSP; Catalogue # AM16704) were 
obtained from Ambion (Austin, TX) SYBR Green Supermix were supplied by Bio-Rad 
(Hercules, CA). Ethylenediamine tetraacetic acid (EDTA) and all other materials were obtained 
from Fisher Scientific (Carlsbad, CA). Human breast cancer cell line MDA-MB-231 (ATCC 
#HTB-26) was purchased from American Type Culture Collection (ATCC; Manassas, VA). 
MDA-MB-231 was cultured in DMEM medium. Media were supplemented with 10% (v/v) fetal 
bovine serum, 100 U/mL penicillin and 100 μg/ml streptomycin. Cells were maintained in the 
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normal condition of 37 °C and 5% CO2 under humidified atmosphere and were sub-cultured 
when 80-100% confluent. 
2.2. Synthesis of fatty acyl-CGKRK peptides  
  In general, the CGKRK peptide was synthesized using solid-phase synthesis strategy 
employing N-(9-fluorenyl)methoxy-carbonyl (Fmoc)-based peptide chemistry. Fmoc-L-amino 
acids were used as building blocks. The CGKRK peptide sequence was synthesized on Tribute 
automated peptide synthesizer (Protein Technology, Inc., Arizona) in 0.40 mmol scale. The fatty 
acylation was performed on a solid support using palmitic acid, stearic acid, and oleic acid. 
HTBU and DIPEA were used as coupling reagents as reported [24]. The mass of synthesized 
peptide was fully characterized using high-resolution matrix-assisted laser desorption−ionization 
time-of-flight (MALDI-TOF/TOF) mass spectrometer (ABX SCIEX TOF/TOF) and lyophilized 
before using to conjugate chitosan.  
 
2.3. Synthesis of COS-SMCC 
The coupling of COS to sulfo-SMCC was carried out as reported [25]. The resulted COS-
SMCC was purified using dialysis tube (MWCO 1000 Da) against distilled water for 3 days and 
freeze-dried affording COS-SMCC as a powder. 
 
2.4.  Synthesis of fatty acyl-CGKRK-COS  
 In brief, 50 mg of COS-SMCC was dissolved in 10 mL of phosphate buffer solution at 
pH 6.5 and stirred for 30 min. Then, the solution of a fatty acyl-CGKRK peptide (2 mM) in PBS 
with pH 6.5 was added dropwise over 30 min. The conjugation reaction was continued under 
stirring for an additional 48 h at room temperature in the dark. The resulting fatty acyl-CGKRK-
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COS conjugates were purified using dialysis tube with MWCO 1000 Da for three days against 
MilliQ-water. Then, the dialyzed polymers were freeze-dried to obtain the corresponding fatty 
acyl-CGKRK-COS powder for further biological assays. 
 
2.5.  FT-IR  
 FT-IR spectra for COS, COS-SMCC, and fatty acyl-CGKRK-COS were obtained with 
(Alpha FT-IR Spectrometer/Platinum ATR) from Bruker. 
 
2.6. 
13
C NMR  
 13
C NMR spectra for COS, COS-SMCC, and fatty acyl-CGKRK-COS were recorded on 
a Bruker Avance III HDTM 400 NMR spectrometer in D2O. Chemical shifts are shown in parts 
per million (ppm).  
 
2.7. Scanning electron microscopy (SEM) 
 The samples of COS, COS-SMCC, and fatty acyl-CGKRK-COS were imaged with a 
SEM Phillips XL-30 scanning electron microscope, UCI, California, USA, by sprinkling onto an 
aluminum stub covered with copper tape. 
 
2.8. Preparation of polymer/siRNA nano polyplexes 
The polymer/siRNA polyplexes were prepared in 0.15 M NaCl with stock polymer (1 
mg/mL) and scrambled siRNA (0.14 µg/µL) solutions. For complex formation, a solution of 
scrambled siRNA was mixed with the polymer solution at ratios (1:1, 2.5:1, 5:1, and 10:1; w/w). 
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Then they were subjected to gentle vortex for 30 sec and incubated at room temperature for 30 
min before use or further experiments.  
 
2.9. Dynamic light scattering measurements  
Particle size and zeta potential of the different formulations at different polymer:siRNA 
ratio were determined following a dynamic light scattering (DLS) method using Malvern Zeta 
Sizer (Nano ZS; Malvern, Instruments, UK) equipped with photodiode detector at 90°
 
orientation. The nano polyplex were freshly prepared as mentioned in section 2.8, then the 
volume of each sample was completed to 1 mL by adding a saline solution. Then the size and 
zeta potential of the complexes were measured in triplicate at 25 ºC. 
 
2.10. SYBR green dye exclusion assay 
The affinity of the polymers to bind to the siRNA was assessed by the SYBR Green II 
binding assay. Briefly, scrambled siRNA solutions (1.25 µL /100 µL) were prepared in 0.15 M 
NaCl (in duplicate) and the polymer solution (1 mg/mL) was added to the siRNA solution in 
different volumes to create different polymer:siRNA weight ratios from 0.2:1, 0.4:1, 0.8:1, 1.6:1, 
2.4:1, 3.2:1, and 6.4:1. After 30 min incubation at room temperature, 200 µL of the SYBR Green 
II solution was added to the complexes, and the fluorescence of the samples was measured in a 
384 well plate (ex: 485 nm, em: 527 nm) to quantify the amount of free siRNA. The binding 
curves were generated by plotting the percentage of siRNA bound to the polymer vs. polymer to 
siRNA ratio as described above, and the BC50 value was calculated based on the ratio that 
yielded 50% binding under the experimental conditions. 
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2.11. Serum stability and heparin dissociation assays 
Samples of unprotected (naked) scrambled siRNA, and polymer/siRNA nano polyplexes 
were prepared with polymer:siRNA ratios of (2.5:1, 5:1, 7.5:1, and 10:1; Wt/Wt).  The 
polyplexes were incubated in triplicates at 37 
o
C in triplicate with 25% v/v fetal bovine serum 
(FBS) solution in HBSS for 24 h (FBS) for 24 h. At the end of incubation period, 2 µL of 5% 
heparin solution in saline and 3 µL of 0.5 mM EDTA solution were added to the samples and 
incubated at 37 
o
C for 1 h to ensure complete dissociation of remaining siRNA from the 
polymers. Samples were then analyzed for the remaining intact siRNA by agarose gel 
electrophoresis using 1% agarose gel containing 1 μg/mL ethidium bromide (EtBr) at 70 V for 
20 min. The gel was visualized under UV illumination (Gel-Doc system, Bio-Rad; Hercules, 
CA), and the intensity of the bands corresponding to the remaining intact siRNA was quantified 
using Image J software, and digitalized pictures were analyzed with Scion Image analysis 
software to determine the siRNA band density. 
 
2.12. Cytotoxicity of the polymer and the polymer/siRNA polyplexes  
Polymer/siRNA complexes were prepared using the scrambled siRNA at the ratio of 8:1 
and added to the wells to give final polymer concentrations of 1.25, 2.5, 5, and 10 µg/ mL in 
triplicate. Then, the cells were incubated for 48 h in their normal maintenance conditions, and 
then 40 µL of MTT solution (5 µg/ mL in HBSS) was added to each well. After 2 h of incubation 
in 37 
o
C, the medium was removed, and 500 µL of DMSO was added to each well to dissolve the 
formed crystals. The optical density of the wells was measured with UV-2600 (UV-Vis 
Spectrophotometer, Shimadzu, USA) with the cell-less medium as a blank. The absorbance of 
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polymer treated cells was compared to untreated cells (as 100% viability), and the percent of cell 
viability was calculated for each concentration of polymers. 
 
3. Results and Discussion 
The success of CGKRK peptide in achieving selective delivery of many biologically active 
molecules such as anticancer drugs and siRNA to the tumor tissues [22-24, 26] promoted our 
research group to explore the potential efficacy of this short peptide in different formulations to 
target siRNA to different cancer cells. Recently, we have developed a library of fatty acyl (Fa) 
CGKRK peptides which were found potent in their ability to bind to siRNA. The palmitoyl-
CGKRK (P-CGKRK), stearoyl-CGKRK (S-CGKRK), and oleoyl-CGKRK (O-CGKRK) 
peptides showed promising efficacy in mediate siRNA transfection, gene silencing, and in vitro 
tumor selectivity when investigated on prostate, breast cancer cell lines, and healthy kidney cell 
line [24]. Therefore, we selected these three Fa-CGKRK derivatives and coupled them to COS to 
investigate the impact of using COS in forming complexes with siRNA and its ability in the 
protection of siRNA from serum RNas.  
In this study, the water soluble and reactive COS with the average molecular weight 4000-
5000 Da, and degree of deacetylation 90% was used as a carrier for siRNA. However, the lack of 
selectivity, limited cellular uptake and transfection efficacy of COS encouraged us to modify 
COS by coupling three different fatty acyl-CGKRK peptides via a sulfo-SMCC bifunctional 
linker (Scheme 1).  
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3.1. Coupling of COS to fatty acyl-CGKRK 
  The strategy first involved the immobilization of the bifunctional linker (sulfo-SMCC) on 
the surface of the water-soluble COS as described by us to form COS-SMCC [21]. Three fatty 
acyl-CGKRK peptides namely, P-CGKRK, S-CGKRK, and O-CGKRK were synthesized and 
characterized as reported by us. [24]. Then, Fa-CGKRK peptides were coupled through the 
formation of stable thioether bond between the peptide reduced sulfhydryl groups and the 
maleimide arm of COS-SMCC (Scheme 1). The structures of the new conjugates were confirmed 
by FT-IR, 
13
C NMR, and SEM.  
3.2. Characterization for fatty acyl-CGKRK-COS 
3.2.1. FT-IR of the conjugates: 
FT-IR spectra for COS, COS-SMCC, and fatty acyl-CGKRK-COS confirm the functional 
groups after covalent coupling in the conjugated polymer. As shown in Fig. 1, the FT-IR of COS 
revealed the presence of the following absorption bands at 3240 cm
-1
, 2921 cm
-1
, 1673 cm
-1
, and 
1550 cm
-1
 which were due to the stretching vibrational bands of ـــNH2, CـــH aliphatic, C=O 
acetyl, and the bending vibrational band of N–H respectively. For COS-SMCC, the shift in the 
stretching vibrational bands from 1673 cm
-1 
to 1668 cm
-1
 and the appearance of strong sharp 
absorption band at 1626 cm
-1
 corresponds to the acetyl C=O and the NH-C=O amide I and II due 
to the conjugation between COS, and SMCC. In addition to the bending vibrational band at 1531 
cm
-1
 for N–H group and the two stretching vibrational bands at 1093 cm-1 and 1053 cm-1 which 
was assigned
 
to the different etheric C-O-C bonds. The peak at 674 cm
-1 
revealed the presence of 
the bending maleimide (C-H) band [21, 25, 27]. The coupling of the fatty acyl-CGKRK peptides 
to COS-SMCC was evidenced by the increased intensity of the stretching vibrational bands at 
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2918-2853 cm
-1
 due to the stretching band for aliphatic CــH of the fatty acyl side chains and the 
amino acids side chain. The absorption bands at 1683 cm
-1
, 1633 cm
-1
, 1672 cm
-1
, 1638 cm
-1
, 
1671 cm
-1
, 1625 cm
-1
 were assigned to the symmetric stretching bands of C=O amide bonds and 
C=O acetyl groups for the palmitoyl, stearoyl, and oleoyl COS derivatives. While the bending 
N–H of the deacetylated amine along the chitosan backbone of the three polymer conjugates 
appeared at 1526 cm
-1
, 1526 cm
-1
, and 1523 cm
-1
 respectively.   
 
3.2.2. Structure characterization of conjugates using 
13
C NMR spectroscopy 
 Figure 2 depicts the 13C NMR spectrum for starting material and conjugated compounds 
such as COS, COS-SMCC, and fatty acyl-CGKRK-COS which showed a characteristic peak for 
the structural confirmation of the conjugated compounds. The spectra of COS (D2O) in fig 2a 
revealed the existence of the following signals at δ (ppm) values of 22.08 for CH3 (acetyl), 66.60 
- 101.34 were assigned to carbon atoms C6, C5, C4, C3, C2 and C1 of the anhydroglucose amine 
units, and a single peak for CO (acetyl carbonyl) at 181.87 ppm [26]. The successful conjugation 
of SMCC linker to the COS chain was revealed in fig 2b,  where the characteristic peaks in the 
region of 26.98 - 101.17 ppm were attributed to the SMCC linker, (C1-C6) of chitosan 
anhydroglucose amine units.  The distinctive signal of maleimide arm (HC=CH) appeared at δ 
value of 131.58 ppm [25]. While the signals at δ values in 165.32, 174.75, and 179.01 ppm were 
assigned to the three different CO (amidic carbonyl) and one CO (acetyl carbonyl) groups of 
COS-SMCC chains [21]. The coupling of fatty acyl-CGKRK peptides to COS-SMCC were 
confirmed by analyzing the 
13
C NMR spectra (fig 2c-2e) which revealed the appearance of a new 
signal at δ (ppm) values at 16.57, 16.54, and 13.96 ppm for the terminal CH3 of the palmitoyl, 
stearoyl, and oleoyl chains respectively. Furthermore, the signals at the region 156-178 ppm in 
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fig 2c-d were attributed to the carbonyl groups of CGKRK peptide, chitosan backbone, and those 
of SMCC linker. Additionally, the clear signal in the 
13
C-NMR spectrum of O-CGKRK-COS at 
δ  value of 131.20 ppm was assigned to the oleoyl ethylenic group (CH=CH) [28]. These 13C-
NMR assignments for COS-fatty acyl peptide conjugates were in agreement with the reported 
data in the literature.  
 
3.2.3. Characterization of the copolymer morphology by SEM 
The morphology of COS, COS-SMCC, and the three derivatives of fatty acyl-CGKRK-
COS conjugates were examined and compared to unmodified COS and COS-SMCC by the 
scanning electron microscopy. As shown in Fig. 3a-e, the sequential functionalization of COS 
with SMCC, and fatty acyl-CGKRK changed the morphology of COS from granulated particles 
to fibrous, network like structures with several large pores size. 
 
3.3. Size and zeta potential analysis 
The hydrodynamic size for the polymer/siRNA complexes at different weight ratios of 
the polymers to siRNA was determined as reflected in fig 4a. Overall the hydrodynamic particles 
size varied by varying the polymer ratio, and the hydrophobic moiety conjugated to the CGKRK 
peptide. At ratio 5:1, the polyplexes had particle size ranged from 204-386 nm, and the smallest 
particle size achieved by O-CGKRK-COS. As the polymer: siRNA ratio increase from 5:1 to 
10:1, the two conjugated polymers (P-CGKRK-COS and O-CGKRK-COS) exhibited decrease in 
the hydrodynamic diameter. Meanwhile, S-CGKRK-COS polymer showed increase in 
hydrodynamic diameter (204-274nm). Interesting, S-CGKRK-COS polymer at polymer: siRNA 
ratio of 1:1 showed highest diameter at this ratio as compared to other two polymers. 
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Furthermore, the conjugation of COS to the fatty acyl-CGKRK peptide efficiently improved the 
complexing ability with siRNA and potentially reduced the hydrodynamic size to less than 200 
nm at a ratio of 10:1 in comparison to the fatty acyl-CGKRK alone which gave nanoplexes with 
hydrodynamic size  300-400 nm at peptide: siRNA ratio of 10: 1 [24] (Fig.4a).  
 The values obtained from zeta potential measurement showed that fatty acyl-CGKRK-
COS polymers had higher zeta potential compared to unmodified COS at the same ratio of 
polymer: siRNA. The increase in the zeta potential in the functionalized polymer can be 
attributed to the increase in average molecular weight of the Fa-CGKRK-COS and the cationic 
nature of the coupled peptide which has two lysine and one arginine moieties. For all Fa-
CGKRK-COS derivatives, a continuous increase in the zeta-potential was observed with 
increasing the polymer:siRNA ratio. All polymers showed positive zeta potential at the ratio of 
5:1 and started to plateau at ratio 10:1, except COS, which had a positive value of 4.3 mv at a 
ratio of 10:1. The data revealed that the oleoyl substitution effectively shifted the zeta potential 
to more positive values compared to the palmitoyl and the stearoyl derivatives which indicates its 
strong ability in assembling with siRNA (Fig. 4b).  
 
3.4. Binding affinity of the polymers to siRNA  
The affinity of each polymer to form complexes with siRNA was determined by SYBR 
green test. The SYBR green dye tends to bind to the uncomplexed (free) siRNA Fig. 5a. The 
results showed that COS had the highest affinity to complex with siRNA compared to the other 
investigated three derivatives of fatty acyl peptide –COS, and this trend was expected due to the 
hydrophilic nature of COS. The binding affinity for the three COS derivatives with increasing 
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ratio were in the following order: unmodified COS > S-CGKRK-COS ≈ O-CGKRK-COS ≈ P-
CGKRK-COS. 
The ratio of polymer: siRNA at which 50% of siRNA binding was achieved, is defined as 
BC50 which was calculated for each polymer from the binding affinity curves. BC50 correlates the 
degree of polymer hydrophobicity to the binding affinity of siRNA. Fig. 5b showed a correlation 
between BC50 and the number of carbon atoms of the attached fatty acid.  It can be concluded 
that the BC50 decreases as in such order: COS < O-CGKRK-COS ≈ S-CGKRK-COS < P-
CGKRK-COS. The calculated BC50 for S-CGKRK-COS and O-CGKRK-COS were almost the 
same and less than the palmitoyl derivative. 
 
3.5. Serum stability test of nano polyplexes 
The carrier system should be able to protect siRNA from degradation by serum RNAase 
A-type nucleases which play a critical role in reducing the circulation half-life of siRNA to less 
than 30 min [27]. The polymer/siRNA complexes were prepared at different weight ratios (2.5, 
5, 7.5, and 10) and incubated in triplicate with 25% FBS solution in HBSS (v/v) for 24 h at 37 
o
C, then the percentage of intact siRNA was determined by agarose gel electrophoresis (Fig. 6). 
A regular trend in the increase of siRNA protection from serum lytic enzymes was achieved at 
polymer: siRNA ratios of 2.5:1, 5.0:1, 7.5:1, and 10:1 for all the polymers whereas S-CGKRK-
COS showed a minor increase in protection during increase in ratios from 7.5:1 to 10:1. The 
impact of fatty acid conjugation to CGKRK was studied in our previous studies [24], which 
indicated that the attachment of fatty acyl moiety to CGKRK peptide improved its ability to 
protect siRNA from serum RNAas degradation. Although, fatty acyl CGKRK had negligible to 
limited abilities in protecting siRNA (0% to less than 55%) at peptide:siRNA w/w ratios of 5:1 
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(N/P ≈ 6.8), and 10:1 (N/P ≈ 13.6), however all the conjugates, e.g., Fa-CGKRK-COS achieved 
different degrees of protection for siRNA. Our experiments revealed that degree of serum 
degradation was dependent on the polymer ratio and its degree of hydrophobicity. Generally, 
increasing the polymer ratio increased its ability to protect siRNA from serum degradation. 
Where COS protected 98.7% of siRNA at polymer ratio 10. Meanwhile, the palmitoyl, oleoyl, 
and stearoyl derivatives protected about 91.6, 94.7 and 98% of siRNA
 
at the
 
same polymer ratios. 
In conclusion, the conjugation of COS to the fatty acyl peptides exerted a positive effect in 
stabilizing and protecting siRNA from degradation the fatty acyl peptide to siRNA.  
 
3.6  Evaluation of cytotoxicity of the polymer and polymer/siRNA polyplexes 
The cytotoxicity of COS, fatty acyl-CGKRK-COS alone, and fatty acyl-CGKRK-
COS/siRNA polyplexes were assessed on human breast cancer cell line MDA-MB-231 using 
MTT assay. The test was carried out at polymer concentrations of 1.25, 2.5, 5, and 10 µg/mL. 
All polymers showed a safer toxicity profile at 1.25 µg/ml, however at the highest concentration 
used 10 µg/ml, COS, and O-CGKRK-COS derivative exhibited a mild toxicity by 25% and 14% 
respectively. The toxicity of COS increase by increasing its concentration. Meanwhile, the 
cytotoxicity of both P-CGKRK-COS and S-CGKRK-COS were almost negligible at all 
investigated concentrations, as shown in Fig. 7a. Regarding the cytotoxicity of polymers/siRNA 
complexes, a negligible cytotoxicity was observed for the polyplexes at all investigated ratios 
except for the polyplexes prepared with palmitoyl and oleoyl derivatives which displayed a mild 
toxicity profile by 35.6% and 21.5% at the polymer/siRNA ratio of 10:1 respectively (Fig. 7b).  
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4. Conclusions 
Using sulfo-SMCC linker, we have successfully immobilized fatty acyl-CGKRK peptide 
motif on the surface of chitosan oligosaccharide aiming to improve the efficacy of fatty acyl-
CGKRK as a siRNA carrier system. The structure of the new polymers constructs were 
elucidated by FT-IR, 
13
C NMR, and SEM. The new Fa-CGKRK-COS derivatives displayed 
improved siRNA binding affinities. The results suggested that Fa-CGKRK-COS conjugates were 
able to protect siRNA from the degradation by the serum lytic enzymes, particularly at high 
polymer ratio better than COS and Fa-CGKRK peptides alone. Additionally, the polyplexes with 
siRNA did not exhibit significant cytotoxicity even at the high polymer concentrations. It could 
be concluded that O-CGKRK-COS is promising carrier system for selective delivery of siRNA 
to the multi-drugs resistant breast cancer cell line. The ability of O-CGKRK-COS to mediated 
selective siRNA transfection in MDA-231 will be studied in future work. 
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Captions 
Scheme 1: The synthesis of conjugated fatty acyl-CGKRK-COS. 
 
Figures Legends: 
Fig. 1: FT-IR for (a) COS, (b) COS-SMCC, (c) P-CGKRK-COS, (d) S-CGKRK-COS, and (e) 
O-CGKRK-COS. 
Fig. 2: 
13
C NMR (D2O) for (a) COS, (b) COS-SMCC, (c) P-CGKRK-COS, (d) S-CGKRK-COS, 
and (e) O-CGKRK-COS. 
Fig. 3: SEM of (a) COS, (b) COS-SMCC, (c) P-CGKRK-COS, (d) S-CGKRK-COS, and (e) O-
CGKRK-COS. 
Fig. 4: (a) The polymer/siRNA complexes hydrodynamic size; (b) The zeta potential of 
polymer/siRNA complex. 
Fig. 5: (a) Binding affinity of the copolymers to scrambled siRNA; (b) The correlation between 
the length of the fatty acid conjugate and the polymer: scrambled siRNA ratio required for 50% 
binding.  
Fig. 6: The serum stability of polymer/siRNA complex. 
Fig. 7: (a) The cytotoxicity of COS, P-CGKRK-COS, S-CGKRK-COS, and O-CGKRK-COS 
without siRNA; (b) The cytotoxicity of COS/siRNA, S-CGKRK-COS/siRNA, P-CGKRK-
COS/siRNA, and O-CGKRK-COS/siRNA complexes. 
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